PubRank

Pierre R Burkhard

Author PubWeight™ 59.57‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 VPS35 mutations in Parkinson disease. Am J Hum Genet 2011 4.16
2 Relative quantification of proteins in human cerebrospinal fluids by MS/MS using 6-plex isobaric tags. Anal Chem 2008 3.04
3 Gait assessment in Parkinson's disease: toward an ambulatory system for long-term monitoring. IEEE Trans Biomed Eng 2004 2.32
4 Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 2004 2.19
5 Phantosmias and Parkinson disease. Arch Neurol 2008 2.13
6 PARK7 and nucleoside diphosphate kinase A as plasma markers for the early diagnosis of stroke. Clin Chem 2005 1.94
7 Quantification of tremor and bradykinesia in Parkinson's disease using a novel ambulatory monitoring system. IEEE Trans Biomed Eng 2007 1.68
8 Ambulatory monitoring of physical activities in patients with Parkinson's disease. IEEE Trans Biomed Eng 2007 1.66
9 Levodopa in the treatment of Parkinson's disease: an old drug still going strong. Clin Interv Aging 2010 1.49
10 Skull base cerebrospinal fluid fistula: a novel detection method based on two-dimensional electrophoresis. Head Neck 2004 1.39
11 Fatty acid binding protein as a serum marker for the early diagnosis of stroke: a pilot study. Mol Cell Proteomics 2003 1.12
12 ApoC-I and ApoC-III as potential plasmatic markers to distinguish between ischemic and hemorrhagic stroke. Proteomics 2004 1.11
13 Cystatin C as a potential cerebrospinal fluid marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics 2004 1.09
14 Giant plexiform neurofibroma in neurofibromatosis type 1. Arch Neurol 2010 1.09
15 Identification of post-mortem cerebrospinal fluid proteins as potential biomarkers of ischemia and neurodegeneration. Proteomics 2004 1.07
16 Velocity control in Parkinson's disease: a quantitative analysis of isochrony in scribbling movements. Exp Brain Res 2009 1.06
17 Truncated cystatin C in cerebrospiral fluid: Technical [corrected] artefact or biological process? Proteomics 2005 0.99
18 Restless arms. Lancet 2008 0.99
19 State-of-the-art two-dimensional gel electrophoresis: a key tool of proteomics research. Nat Protoc 2006 0.96
20 Identification of brain cell death associated proteins in human post-mortem cerebrospinal fluid. J Proteome Res 2006 0.94
21 Brain extracellular fluid protein changes in acute stroke patients. J Proteome Res 2011 0.93
22 Long-term cognitive profile and incidence of dementia after STN-DBS in Parkinson's disease. Mov Disord 2007 0.91
23 Ubiquitin fusion degradation protein 1 as a blood marker for the early diagnosis of ischemic stroke. Biomark Insights 2007 0.89
24 Etiologies of Parkinsonism in a century-long autopsy-based cohort. Brain Pathol 2012 0.89
25 A novel approach to reducing number of sensing units for wearable gait analysis systems. IEEE Trans Biomed Eng 2012 0.89
26 Clinical significance of basal ganglia alterations at brain MRI and 1H MRS in cirrhosis and role in the pathogenesis of hepatic encephalopathy. Metab Brain Dis 2002 0.88
27 Proteomics in human Parkinson's disease research. J Proteomics 2009 0.88
28 Neuropathology of dementia in a large cohort of patients with Parkinson's disease. Parkinsonism Relat Disord 2013 0.87
29 Proteomic profiling of the substantia nigra demonstrates CNDP2 overexpression in Parkinson's disease. J Proteomics 2012 0.86
30 A potential cerebrospinal fluid and plasmatic marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics 2003 0.85
31 Exploring the human tear fluid: discovery of new biomarkers in multiple sclerosis. Proteomics Clin Appl 2014 0.84
32 Fulminant Lewy body disease. Mov Disord 2006 0.84
33 Added Value of Combined Semi-Quantitative and Visual [123I]FP-CIT SPECT Analyses for the Diagnosis of Dementia With Lewy Bodies. Clin Nucl Med 2016 0.84
34 Does subthalamic nucleus deep brain stimulation really improve quality of life in Parkinson's disease? Mov Disord 2006 0.83
35 Pluripotent stem cells as new drugs? The example of Parkinson's disease. Int J Pharm 2009 0.83
36 Compulsive singing: another aspect of punding in Parkinson's disease. Ann Neurol 2007 0.83
37 Age-related proteome analysis of the mouse brain: a 2-DE study. Proteomics 2006 0.83
38 Prostaglandin D2 synthase and its post-translational modifications in neurological disorders. Electrophoresis 2005 0.83
39 Long-duration response to levodopa in patients with advanced Parkinson disease treated with subthalamic deep brain stimulation. Arch Neurol 2006 0.83
40 Proteomic analysis of human substantia nigra identifies novel candidates involved in Parkinson's disease pathogenesis. Proteomics 2014 0.82
41 Blood glutathione S-transferase-π as a time indicator of stroke onset. PLoS One 2012 0.81
42 TNF-alpha and psychologically stressful events in healthy subjects: potential relevance for multiple sclerosis relapse. Behav Neurosci 2002 0.81
43 Regions of interest-based discriminant analysis of DaTSCAN SPECT and FDG-PET for the classification of dementia. Clin Nucl Med 2013 0.80
44 Hippocampal atrophy predicts conversion to dementia after STN-DBS in Parkinson's disease. Parkinsonism Relat Disord 2009 0.80
45 Delayed leukoencephalopathy after alprazolam and methadone overdose: a case report and review of the literature. Clin Neurol Neurosurg 2012 0.80
46 Dyskinesia-induced postural instability in Parkinson's disease. Parkinsonism Relat Disord 2008 0.80
47 Successful long-term bilateral subthalamic nucleus deep brain stimulation in VPS35 Parkinson's disease. Parkinsonism Relat Disord 2013 0.79
48 Anti-(apolipoprotein A-1) IgGs are associated with high levels of oxidized low-density lipoprotein in acute coronary syndrome. Clin Sci (Lond) 2008 0.79
49 Clinical assessment of motor function: a processes oriented instrument based on a speed-accuracy trade-off paradigm. Behav Neurol 2007 0.79
50 A capillary blood ammonia bedside test following glutamine load to improve the diagnosis of hepatic encephalopathy in cirrhosis. BMC Gastroenterol 2011 0.78
51 Neuroproteomics and Parkinson's disease: don't forget human samples. Expert Rev Proteomics 2011 0.78
52 Expanding the phenotype of fragile X-associated tremor/ataxia syndrome: a new female case. Mov Disord 2007 0.77
53 [Parkinson disease: description of an interdisciplinary program of functional group rehabilitation]. Rev Med Suisse Romande 2003 0.77
54 Brueghel syndrome as a new manifestation of HIV encephalopathy. Eur Neurol 2008 0.76
55 From relative to absolute quantification of tryptic peptides with tandem mass tags: application to cerebrospinal fluid. Chimia (Aarau) 2010 0.76
56 Retronasal olfactory function in Parkinson's disease. Laryngoscope 2009 0.75
57 Rhinorrhea and olfaction in Parkinson disease. Neurology 2008 0.75
58 Neuropathology of Parkinsonism in Alzheimer's disease. Adv Exp Med Biol 2015 0.75
59 123I-FP-CIT SPECT Accurately Distinguishes Parkinsonian From Cerebellar Variant of Multiple System Atrophy. Clin Nucl Med 2017 0.75
60 [Deep brain stimulation and "translational revolution": the central role of clinicians]. Rev Med Suisse 2015 0.75
61 [Kinesiologic analysis of gait and abnormal movements]. Rev Med Suisse Romande 2003 0.75
62 [Diseases of the peripheral nervous system]. Rev Med Suisse 2007 0.75
63 [Resistance to treatment in movement disorders]. Rev Med Suisse 2012 0.75
64 Stroke severity and residual flow determined by transcranial colour-coded ultrasound (TCCD) predict recanalization and clinical outcome during thrombolysis. J Neurol Sci 2010 0.75
65 Comparison of gel-based methods for the detection of cerebrospinal fluid rhinorrhea. Clin Chim Acta 2012 0.75
66 Foot dystonia as the only manifestation of unilateral nigral atrophy. Mov Disord 2008 0.75